|
Costa Rica HPV Vaccine Trial (IR Travel)
|
Cures Moonshot18I2
|
$89,783
|
N/A
|
N/A
|
|
Costa Rica HPV Vaccine Trial (IR)
|
Cures Moonshot18I3
|
$1,078,107
|
N/A
|
N/A
|
|
IDDA - Partner - CDC
|
NIH-18-013
|
$678,899
|
N/A
|
N/A
|
|
IDDA - Partner - HRSA
|
NIH-18-017
|
$700,000
|
N/A
|
N/A
|
|
IDDA - Partner - CDC
|
NIH-18-018
|
$74,250
|
N/A
|
N/A
|
|
IDDA - Partner - CDC
|
NIH-18-025
|
$127,224
|
N/A
|
N/A
|
|
IGF::OT::IGF Hosting, Maintenance and Professional services for Rave and Medidata Rave Integrated Software
|
261201800033I
|
$5,576,825
|
-, -
|
-
|
|
The purpose of this procurement is to provide strategic planning and support service for the NCI CBITT
|
261201800285P
|
$24,876
|
-, -
|
-
|
|
Electronic Capture of Cancer Claims Data for SEER Program
|
261201800649P
|
$245,000
|
-, -
|
-
|
|
RIESSEARCH, LLC:1164941 [18-046091]
|
261201800744P
|
$22,800
|
-, -
|
-
|
|
IGF::OT::IGF CORE SUPPORT ACTIVITIES: SCIENTIFIC WRITING, TECHNICAL AND LOGISTICAL SUPPORT SERVICES
|
261201700004I
|
$1,200,000
|
BIZZELL, ANTON
|
-
|
|
BUSINESS ANALYST SERVICES TO ACHIEVE A BETTER UNDERSTANDING OF THE BUSINESS PROCESSES OF THE THE FEDERALLY FUNDED RESEARCH AND DEVELOPMENT CENTER (FFRDC) CONTRACTORS BUSINESS SYSTEMS.
|
261201800005A
|
$315,922
|
DURAND, HANK
|
-
|
|
CBCSLC CONTRACT FOR THE NCI CHEMICAL BIOLOGY CONSORTIUM, TO# 1
|
261201500010I
|
$275,323
|
JOHNSON, CHARLES
|
-
|
|
IGF::OT::IGF OPERATION & SUPPORT OF THE CTEP PROTOCOL AND INFORMATION OFFICE (PIO)
|
261201600003C
|
$1,232,875
|
KIERNAN, SHERYL
|
-
|
|
IGF::OT::IGF OTHER FUNCTIONS - IRB MANAGER SOFTWARE. OPTION YEAR TWO
|
261201600195P
|
$168,000
|
LEVERICH, WALDEN
|
-
|
|
IGF::OT::IGF CABEZON GROUP INC:1133841 [16-038312]
|
261201200005I
|
$50,125
|
RATEL, RACHEL
|
-
|
|
Exosomal Drug Delivery
|
5R44CA221487-02
|
$1,000,000
|
SPENCER, WENDY
|
3P BIOTECHNOLOGIES, INC.
|
|
Compact Navigation System for CT-guided Needle Interventions
|
1UT1CA224886-01A1
|
$149,927
|
TSE, TSZ HO
|
3T TECHNOLOGIES, LLC
|
|
Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer
|
2R42CA203456-02A1
|
$999,501
|
MARATHI, UPENDRA
|
7 HILLS PHARMA, LLC
|
|
Pharmacology & human Phase 1 safety & dose escalation studies using anti-GP88 in aggressive breast cancer
|
1R44CA224718-01A1
|
$159,365
|
SERRERO, GINETTE
|
A AND G PHARMACEUTICAL, INC.
|
|
A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer
|
2R44CA210817-02
|
$1,101,350
|
SERRERO, GINETTE
|
A AND G PHARMACEUTICAL, INC.
|
|
Targeted Therapy for Non Small Cell Lung Carcinoma: Human Phase 1 safety and dose escalation studies
|
5R44CA162629-03
|
$833,374
|
SERRERO, GINETTE
|
A AND G PHARMACEUTICAL, INC.
|
|
AVGN7, a Novel Gene Therapeutic for Treating Cancer Cachexia
|
5R44CA221539-02
|
$660,235
|
RODGERS, BUEL
|
AAVOGEN, INC.
|
|
Affinity Purification of Biologics with Mimetope Peptides
|
1R43CA228945-01
|
$217,898
|
MESSMER, BRADLEY
|
ABREOS BIOSCIENCES, INC.
|
|
Personalized precision dosing of biologic therapies in oncology
|
5R44CA217336-02
|
$720,363
|
MESSMER, BRADLEY
|
ABREOS BIOSCIENCES, INC.
|
|
Novel targeted therapy for pancreatic cancer
|
1R43CA221555-01A1
|
$299,979
|
HERRERA, VICTORIA
|
ABTELUM BIOMEDICAL, INC.
|
|
TOPIC 373 - PHASE I SBIR - ABZYME THERAPEUTICS, LLC - Moonshot
|
261201800031C
|
$299,999
|
N/A
|
ABZYME THERAPEUTICS, LLC
|
|
IGF::OT::IGF OTHER FUNCTIONS. Healthcare Delivery Research Visiting Scholars Program.
|
261201800642P
|
$51,283
|
-, -
|
ACADEMYHEALTH
|
|
Novel Glyco-tests to Predict Chemoresistance
|
3R43CA213766-01A1S1
|
$50,000
|
RAZI, NAHID
|
ACCUDAVA, INC.
|
|
Novel Glyco-tests to Predict Chemoresistance
|
3R43CA213766-01A1S2
|
$149,785
|
RAZI, NAHID
|
ACCUDAVA, INC.
|
|
The Madrina Network Web Portal
|
3R44CA177037-03S1
|
$34,313
|
MATIELLA, ANA
|
ACMA SOCIAL MARKETING
|
|
Image-guided ultrasound ablation for precision targeting of prostate cancer
|
1R01CA230323-01
|
$580,217
|
BURDETTE, EVERETTE
|
ACOUSTIC MEDSYSTEMS, INC.
|
|
Innovation Corp Program and Commercialization Planning for Endoscopic Flexible Pancreatic Tumor Ablation System with Reduced Force Effector and Specialized Ablation Zone
|
3R43CA225169-01S1
|
$49,999
|
SNOOK, KEVIN
|
ACTUATED MEDICAL, INC.
|
|
Fluorescent Nanodiamonds for Multiplexed Imaging and Diagnostics
|
1R43CA232901-01
|
$291,083
|
SHENDEROVA, OLGA
|
ADAMAS NANOTECHNOLOGIES, INC.
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
2R44CA200161-02A1
|
$1,000,000
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
3R41CA200161-01A1S3
|
$3,000
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
IeDEA West Africa Renewal 3
|
5U01AI069919-13
|
$225,000
|
DABIS, FRANCOIS
|
ADERA
|
|
Oral formulation for novel inhibitor of Ras driven cancers
|
3R43CA217502-01A1S1
|
$2,000
|
CANZONERI, JOSHUA
|
ADT PHARMACEUTICALS, LLC
|
|
Implantable iontophoresis chemotherapy delivery device for direct infusion of gemcitabine into pancreatic adenocarcinoma: Device development and First-in-Human clinical trial
|
4R44CA224460-02
|
$1,111,364
|
DAUNCH, WILLIAM
|
ADVANCED CHEMOTHERAPY TECHNOLOGIES, INC.
|
|
Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation
|
4R44CA203336-02
|
$659,516
|
AGUILAR-CORDOVA, ESTUARDO
|
ADVANTAGENE, INC
|
|
The Hemopurifier Device for Targeted Removal of Breast Cancer Exosomes from the Blood Circulation
|
1R43CA232977-01
|
$298,444
|
MARLEAU, ANNETTE
|
AETHLON MEDICAL, INC.
|
|
Training African Pathologists in Cancer Diagnosis
|
1R13CA232439-01
|
$38,120
|
WILSON, MICHAEL
|
AFRICAN STRATEGIES /ADVANCING PATHOLOGY
|
|
A Novel Immunotherapy Targeting Cancer Stem Cells for the Treatment of Triple-Negative Breast Cancer
|
1R44CA224835-01A1
|
$298,864
|
PERICLE, FEDERICA
|
AGILVAX, INC.
|
|
Distance Education to Engage Alaskan Community Health Aides in Cancer Control
|
5R25CA186882-05
|
$135,579
|
CUEVA, MELANY
|
ALASKA NATIVE TRIBAL HEALTH CONSORTIUM
|
|
Integrin Regulation of Cancer Progression Through Alternative mRNA Splicing and Nonsense-Medidated Decay (NMD)
|
5R01CA129637-08
|
$375,250
|
DIPERSIO, C MICHAEL
|
ALBANY MEDICAL COLLEGE
|
|
Novel Strategies for Precision T-cell Therapies
|
3R01CA198095-03S1
|
$107,431
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Novel Strategies for Precision T-cell Therapies
|
5R01CA198095-03
|
$520,564
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Womens Interagency HIV Study (WIHS-V)
|
3U01AI035004-25S1
|
$144,370
|
ANASTOS, KATHRYN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Central Africa International Epidemiologic Database to Evaluate AIDS
|
5U01AI096299-09
|
$260,000
|
ANASTOS, KATHRYN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
HIV/HPV Cancer Prevention, Treatment & Pathogenesis: Rwanda/Einstein Consortium
|
5U54CA190163-05
|
$701,988
|
ANASTOS, KATHRYN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|